[go: up one dir, main page]

MX2010003868A - Cis-imidazolinas quirales. - Google Patents

Cis-imidazolinas quirales.

Info

Publication number
MX2010003868A
MX2010003868A MX2010003868A MX2010003868A MX2010003868A MX 2010003868 A MX2010003868 A MX 2010003868A MX 2010003868 A MX2010003868 A MX 2010003868A MX 2010003868 A MX2010003868 A MX 2010003868A MX 2010003868 A MX2010003868 A MX 2010003868A
Authority
MX
Mexico
Prior art keywords
sup
imidazolines
compounds
chiral cis
agents
Prior art date
Application number
MX2010003868A
Other languages
English (en)
Inventor
Allen John Lovey
Binh Thanh Vu
Jianping Cai
David Joseph Bartkovitz
Chunlin Zhao
Xin-Jie Chu
Hongju Li
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40149549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010003868A publication Critical patent/MX2010003868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de la f?rmula (ver f?rmula I) o sus sales farmac?uticamente aceptables, en la que X, Y, Z, V1, V2, R1, R2, R3, R4 y R5 tienen los significados aqu? descritos, procesos para obtener dichos compuestos y preparaciones farmac?uticas que los contienen. Estos compuestos son ?tiles como agentes anticancerosos, en particular como agentes para el tratamiento de tumores s?lidos.
MX2010003868A 2007-10-09 2008-09-30 Cis-imidazolinas quirales. MX2010003868A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97850607P 2007-10-09 2007-10-09
US9275908P 2008-08-29 2008-08-29
PCT/EP2008/063053 WO2009047161A1 (en) 2007-10-09 2008-09-30 Chiral cis-imidazolines

Publications (1)

Publication Number Publication Date
MX2010003868A true MX2010003868A (es) 2010-04-27

Family

ID=40149549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003868A MX2010003868A (es) 2007-10-09 2008-09-30 Cis-imidazolinas quirales.

Country Status (20)

Country Link
US (1) US8513239B2 (es)
EP (2) EP2325180A1 (es)
JP (1) JP5324586B2 (es)
KR (1) KR101203020B1 (es)
CN (2) CN104710408A (es)
AR (1) AR068742A1 (es)
AU (1) AU2008309759A1 (es)
BR (1) BRPI0817850A2 (es)
CA (1) CA2701932C (es)
CL (1) CL2008002982A1 (es)
CO (1) CO6280486A2 (es)
CR (1) CR11333A (es)
ES (1) ES2395210T3 (es)
IL (1) IL204653A0 (es)
MA (1) MA31754B1 (es)
MX (1) MX2010003868A (es)
PE (1) PE20090814A1 (es)
RU (1) RU2487127C2 (es)
TW (1) TW200916446A (es)
WO (1) WO2009047161A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080864A1 (en) * 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
WO2010132873A2 (en) * 2009-05-15 2010-11-18 Northwestern University Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase
US20130143905A1 (en) 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
PE20121614A1 (es) 2009-12-17 2012-12-21 Boehringer Ingelheim Int Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
ES2685175T3 (es) 2010-09-30 2018-10-05 St. Jude Children's Research Hospital Imidazoles sustituidos con arilo
EP2651976A1 (en) * 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
WO2014082889A1 (en) * 2012-11-28 2014-06-05 F. Hoffmann-La Roche Ag Novel imidazolines as dual inhibitors of mdm2 and mdmx
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
PL3415802T3 (pl) 2017-06-14 2020-03-31 Borealis Ag Dylatacja
WO2019186358A1 (en) * 2018-03-26 2019-10-03 Novartis Ag 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
JP2022540678A (ja) 2019-07-16 2022-09-16 マイオカーディア，インク （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体
AU2021268223B2 (en) * 2020-05-07 2025-10-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
ES2301717T3 (es) 2001-12-18 2008-07-01 F. Hoffmann-La Roche Ag Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
ES2307822T3 (es) * 2001-12-18 2008-12-01 F. Hoffmann-La Roche Ag Cis-imidazolinas como inhibidores de mdm2.
DE602005011132D1 (de) 2004-05-18 2009-01-02 Hoffmann La Roche Neuartige cis-imidazoline
CN101238287B (zh) 2005-07-08 2011-05-11 维斯塔斯风力系统有限公司 风轮机、风轮机用的轮毂及其使用
JP4870778B2 (ja) 2005-12-01 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー 抗ガン剤として使用されるｐ５３およびｍｄｍ２タンパク質間の相互作用の阻害剤としての２，４，５−トリフェニルイミダゾリン誘導体
CA2636824A1 (en) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4,5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors

Also Published As

Publication number Publication date
RU2010118018A (ru) 2011-11-20
CR11333A (es) 2010-06-21
JP5324586B2 (ja) 2013-10-23
AR068742A1 (es) 2009-12-02
EP2203437B1 (en) 2012-11-07
CA2701932A1 (en) 2009-04-16
PE20090814A1 (es) 2009-06-27
JP2010540675A (ja) 2010-12-24
CO6280486A2 (es) 2011-05-20
US20090111789A1 (en) 2009-04-30
TW200916446A (en) 2009-04-16
KR101203020B1 (ko) 2012-11-20
MA31754B1 (fr) 2010-10-01
RU2487127C2 (ru) 2013-07-10
ES2395210T3 (es) 2013-02-11
EP2325180A1 (en) 2011-05-25
CN104710408A (zh) 2015-06-17
US8513239B2 (en) 2013-08-20
BRPI0817850A2 (pt) 2015-04-07
EP2203437A1 (en) 2010-07-07
WO2009047161A1 (en) 2009-04-16
CN101821251A (zh) 2010-09-01
CL2008002982A1 (es) 2009-10-16
KR20100051742A (ko) 2010-05-17
IL204653A0 (en) 2010-11-30
CA2701932C (en) 2015-10-20
AU2008309759A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
MX2010003868A (es) Cis-imidazolinas quirales.
IL260127B (en) mek inhibitors and methods of using them
TW200640908A (en) Chemical compounds
TW200613243A (en) Novel compounds
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
GEP20125469B (en) Inhibitors of akt activity
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
TW200801003A (en) Novel compounds
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2007087548A3 (en) Chemical compounds
TW200508214A (en) Novel compounds
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
MX2009010082A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
MY140235A (en) New benzimidazole derivatives
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
TW200626553A (en) Novel compounds
TW200738659A (en) Novel compounds
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
TW200639156A (en) New compounds
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors

Legal Events

Date Code Title Description
FG Grant or registration